Sonothrombolysis is Effective for Minimally Invasive Evacuation of Spontaneous ICH

March 2010
MD Conference Express;Mar2010, p18
Academic Journal
The article focuses on the results of the Safety of Lysis with EKOS Ultrasound in the Treatment of Intracerebral and Intraventricular Hemorrhage (SLEUTH) study by David W. Newell. It states that the results show the help of ultrasound in clot dissolution and tissue plasminogen activator (tPA). Moreover, the results justify the clinical trials of catheter drainage of intraventricular hemorrhage (IVH) and intracerebral hemorrhage (ICH) used in continuous ultrasound.


Related Articles

  • Commentary. Hunt, C. David // Surgical Neurology International;Jan2014, Vol. 5 Issue 1, p438 

    The author discusses aspects of the three cases of chronic encapsulated intracerebral hematoma in the English literature with clinical and radiological diagnosis.

  • Alteplase/aspirin/clopidogrel.  // Reactions Weekly;10/3/2009, Issue 1272, p6 

    The article discusses case reports of two elderly patients who developed symptomatic intracerebral haemorrhage after receiving IV alteplase for treatment of thrombolysis in acute ischaemic stroke. In the retrospective study, the two patients were receiving combined pre-treatment with clopidogrel...

  • Recombinant tissue plasminogen activator to prevent dialysis catheter blockage or infection.  // Africa Health;May2011, Vol. 33 Issue 4, p62 

    The article reports that recombinant tissue plasminogen activator such as heparin has been suggested as an alternative catheter locking solution to prevent catheter blockage or infection after dialysis.

  • Hemorrhagic Transformation And A New Ischemic Accident During Thrombolysis Treatment With rtPA. Hernandez, A.; Rochera, M. I.; Angles, R.; Farre, M.; Caballero, J. // Internet Journal of Emergency & Intensive Care Medicine;2006, Vol. 9 Issue 2, p6 

    Administration of intravenous recombinant tissue plasminogen activation ( rtPA ) administered within 3 hours of symptom onset is an effective therapy for acute ischemic stroke[1][2]. The efficacy of thrombolysis has been demonstrated despite an increased risk of severe hemorrhagic transformation...

  • Evolution of intracerebral hemorrhage after intravenous tPA: reversal of harmful effects with mast cell stabilization. Marinkovic, Ivan; Mattila, Olli S; Strbian, Daniel; Meretoja, Atte; Shekhar, Shashank; Saksi, Jani; Abo-Ramadan, Usama; Rantanen, Ville; Lindsberg, Perttu J; Tatlisumak, Turgut // Journal of Cerebral Blood Flow & Metabolism;Jan2014, Vol. 34 Issue 1, p176 

    Thrombolysis with tissue plasminogen activator (tPA) traditionally demands baseline imaging to rule out intracerebral hemorrhage (ICH), which causes delays in treatment. Preventing possible adverse effects of tPA on ICH would allow rapid on-site thrombolysis in patients with presumed acute...

  • Intravenous tPA Therapy Does Not Worsen Acute Intracerebral Hemorrhage in Mice. Foerch, Christian; Rosidi, Nathanael L.; Schlunk, Frieder; Lauer, Arne; Cianchetti, Flor A.; Mandeville, Emiri; Arai, Ken; Yigitkanli, Kazim; Fan, Xiang; Wang, Xiaoying; van Leyen, Klaus; Steinmetz, Helmuth; Schaffer, Chris B.; Lo, Eng H. // PLoS ONE;Feb2013, Vol. 8 Issue 2, p1 

    Tissue plasminogen activator (tPA) is the only FDA-approved treatment for reperfusing ischemic strokes. But widespread use of tPA is still limited by fears of inadvertently administering tPA in patients with intracerebral hemorrhage (ICH). Surprisingly, however, the assumption that tPA will...

  • Intra-arterial Therapy for Acute Stroke: Trials and Tribulations. Jayaraman, Mahesh V.; Haas, Richard A.; Ahn, Sun H. // Medicine & Health Rhode Island;Dec2011, Vol. 94 Issue 12, p357 

    The article examines the treatment of acute ischemic stroke with intra-arterial therapy (IAT). A brief history on the significance of thombolysis and thombectomy in the management of stroke is offered. The NINDS IV trial is highlighted which evaluates the effectivness of a tissue plasminogen...

  • Randomised Controlled Trial of Recombinant Tissue Plasminogen Activator Versus Urokinase in the Treatment of Acute Pulmonary Embolism.  // JAMA: Journal of the American Medical Association;3/10/89, Vol. 261 Issue 10, p1438 

    Discusses the abstract of a research study concerning randomized controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Principal end points of the comparison; Complications caused by urokinase infusions on several patients.

  • Tissue plasminogen activator versus heparin for locking dialysis catheters: A systematic review. Firwana, Belal M.; Hasan, Rim; Ferwana, Mazen; Varon, Joseph; Stern, Aaron; Gidwani, Umesh // Avicenna Journal of Medicine;2011, Vol. 1 Issue 2, p29 

    Background and Objectives: Hemodialysis catheters are commonly used when renal replacement therapy is initiated. These catheters have significant complications. Among "locking" solutions used in an attempt to decrease these complications is recombinant tissue plasminogen activator (rt-PA). This...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics